Lead Product(s): NM26-2198
Therapeutic Area: Dermatology Product Name: NM26-2198
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Kaken Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 13, 2021
Under the expanded agreement, Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, and the rest of the world.